Silobreaker.com    Log In
   My Page    Help   
360° SearchNetworkHot SpotsTrends
 
Advanced Search Options >>
Saturday, November 21, 2009 4:48 PM

Daiichi Sankyo Co Ltd

Type: Company
Name: Daiichi Sankyo Co Ltd (Daiichi Sankyo Company Limited)
First Reported 11/20/2009 - Updated 11/20/2009 - 1 Documents
Rich' n Famous: Top six under-40 billionaires of India
The release of the Forbes list of the 100 richest Indians has seen a dramatic rise in the number of billionaires from last year. There are now 52 billionaires in India, 25 more than last year. With a combined fortune of $276 billion, almost one fourth ... [msn.co.in - 11/20/2009]
Entities: Mumbai, India, Net Worth
First Reported 11/20/2009 - Updated 11/20/2009 - 1 Documents (in Medicine)
Effient tabs added as treatment option in 2 clinical guideline updates
Effient (prasugrel) tablets, a new antiplatelet medicine, was added as a treatment option in two clinical guideline updates: one for patients receiving percutaneous coronary intervention (PCI) and a second one for patients with ST elevation myocardial ... [PharmaBiz - 11/20/2009]
First Reported 21 hours ago - Updated 21 hours ago - 1 Documents (in Health)
Ranbaxy Laboratories LTD - Click to view image in its original context
Ranbaxy Laboratories LTD
Ranbaxy recalls over 4,000 cartons of acne drug in US
NEW DELHI: Ranbaxy Laboratories has initiated a voluntary recall of 4,348 cartons of its best-selling drug Sotret (isotretinoin, 40 mg) used to treat acne in the US, as they are a part of one batch of tablets which were found to be ‘out of specificat ... [Economictimes - 21 hours ago]
First Reported 11/18/2009 - Updated 11/18/2009 - 4 Documents (in Health)
Eli Lilly & Company - Click to view image in its original context
Eli Lilly & Company
New Updates to AHA/ACC/SCAI Clinical Guidelines Recommend Treatme...
Company: Eli Lilly & Co. (LLY) Effient(R) (prasugrel) tablets, a new antiplatelet medicine, was added as a treatment option in two clinical guideline updates: one for patients receiving percutaneous coronary intervention (PCI) and a second one for patients ... [Zibb - 11/18/2009]
First Reported 11/16/2009 - Updated 11/16/2009 - 3 Documents
BioInvent signs licensing agreement with Daiichi Sankyo for the discovery and development of ...
BioInvent International has announced that it has entered into a licence and discovery agreement with DAIICHI SANKYO COMPANY, LIMITED for the development of therapeutic antibodies against multiple targetsLund, Sweden | November 13, 2009 | BioInvent International ... [PipelineReview - 11/16/2009]
First Reported 11/15/2009 - Updated 11/15/2009 - 4 Documents (in Health)
Effient(R) Exhibited Greater Antiplatelet Activity than High Dose...
Companies: Daiichi Sankyo Co Ltd (DSKYF), Eli Lilly & Co. (LLY) Results from a new study showed patients with type 2 diabetes mellitus who also had coronary artery disease (CAD) and received a 60 mg loading dose and 10 mg maintenance dose of Effient(R) ... [Zibb - 11/15/2009]
First Reported 11/18/2009 - Updated 11/18/2009 - 2 Documents
Research and Markets: Antibiotics - Global Trends Report: Geographic Coverage and Vertical...
BusinessWire - Research and Markets (http://www.researchandmarkets.com/research/ff5934/antibiotics_glob) has announced the addition of the "Antibiotics - Global Trends" report to their offering.Long-term growth in the global antibiotics market would be ... [Forbes.com - 11/18/2009]
First Reported 11/16/2009 - Updated 11/17/2009 - 2 Documents (in Internet & IT)
Daiichi Levofloxacin Patent Upheld in UK Where Sanofi Benefits
The UK Supreme Court’s decision to let stand a lower court’s ruling that Daiichi Sankyo’s supplementary protection certificate (SPC)for the broad-spectrum antibacterial levofloxacin is valid means Sanofi-Aventis can continue to market the agent in the ... [FDA News - 11/17/2009]
First Reported 11/14/2009 - Updated 11/14/2009 - 1 Documents (in Biotechnology)
BioInvent, Daiichi in Antibody Pact
BioInvent International has entered into a license and discovery agreement with for the development of therapeutic antibodies against multiple targets. Daiichi Sankyo will have access to BioInvent's discovery and development technology platform, n-CoDeR ... [Contract Pharma - 11/14/2009]
First Reported 11/17/2009 - Updated 11/17/2009 - 1 Documents (in Health)
New study shows type-2 diabetes mellitus patients with CAD taking Effient achieve greater platelet
Results from a new study showed patients with type-2 diabetes mellitus who also had coronary artery disease (CAD) and received a 60 mg loading dose and 10 mg maintenance dose of Effient (prasugrel) achieved significantly greater platelet inhibition compared ... [PharmaBiz - 11/17/2009]
First Reported 11/17/2009 - Updated 11/17/2009 - 1 Documents
LILLY (ELI) & COMPANY - Research Update
(PR Newswire Europe) Date: Nov. 15, 2009 Refer to: Derin Denham Eli Lilly and Company +1-317-277-6749 (office) +1-317-370-1435 (cell) Dr. Michaela Paudler-Debus Daiichi Sankyo Europe GmbH +49-(0)89-78 08 685 (office) +49-(0)172-845 8974 (cell) Shigemichi ... [Individual.com - 11/17/2009]
First Reported 11/17/2009 - Updated 11/17/2009 - 1 Documents (in Biotechnology)
BioInvent and Daiichi Sankyo Target Multiple Antibodies
BioInvent International and Daiichi Sankyo have entered into a license and discovery agreement to develop new therapeutic antibodies against multiple targets.The deal will allow Daiichi Sankyo access to BioInvent's discovery and development technology ... [Pharmaceutical Technology - 11/17/2009]

Quotes

...marketed in the United States as Effient, with a Class I rating," said Rogelio Braceras, M D , senior medical director for Daiichi Sankyo, Inc. "Based on the latest clinical studies and scientific evidence, these guidelines provide clear recommendations for how Effient should be incorporated into medical practice to help reduce risk of cardiovascular events such as heart attacks and blood clots forming around stents."
Updated clinical guidelines on Effient treatment for ACS patients [News-Medical.Net - 11/19/2009]

More Content

All (288) | News (262) | Reports (0) | Blogs (21) | Audio/Video (0) | Fact Sheets (2)
sort by: Date | Relevance
FDA approves sNDA for pediatric autism drug ABI... [News-Medical.Net - 11 hours ago]
Ranbaxy recalls over 4,000 cartons of acne drug... [Economictimes - 21 hours ago]
AstraZeneca files Brilinta in US [Pharmafocus - 11/20/2009]
Effient tabs added as treatment option in 2 cli... [PharmaBiz - 11/20/2009]
Rich' n Famous: Top six under-40 billionaires o... [msn.co.in - 11/20/2009]
KineMed Receives an Investigator-Initiated Stud... [Yahoo! Canada - 11/20/2009]
BioInvent and ThromboGenics NV Win "Licens... [BioSpace - 11/19/2009]
AHA: Low Bleeding Rates Observed in Dabigitran ... [MedPage Today - 11/19/2009]
Updated clinical guidelines on Effient treatmen... [News-Medical.Net - 11/19/2009]
New Updates to AHA/ACC/SCAI Clinical Guidelines... [Zibb - 11/18/2009]
New Updates to AHA/ACC/SCAI Clinical Guidelines... [Street Insider - 11/18/2009]
New Updates to AHA/ACC/SCAI Clinical Guidelines... [PR Newswire via MSN Money - 11/18/2009]
New Updates to AHA/ACC/SCAI Clinical Guidelines... [Stockwatch - 11/18/2009]
Research and Markets: Antibiotics - Global Tren... [Forbes.com - 11/18/2009]
Research and Markets: Antibiotics - Global Tren... [Business Wire - 11/18/2009]
Research and Markets: Developing Managed Care P... [RBC Dain Rauscher - 11/18/2009]
Zenotech net loss widens to Rs 3.41 cr [Hindu Business Line - 11/17/2009]
UPDATE 3-FDA warns heartburn drugs interfere wi... [Interactive Investor International - 11/17/2009]
BioInvent and Daiichi Sankyo Target Multiple An... [Pharmaceutical Technology - 11/17/2009]
LILLY (ELI) & COMPANY - Research Update [Individual.com - 11/17/2009]
New study shows type-2 diabetes mellitus patien... [PharmaBiz - 11/17/2009]
Daiichi Levofloxacin Patent Upheld in UK Where ... [FDA News - 11/17/2009]
www.Xtremepicks.Com: Xtremepicks Alerts Novembe... [Pharmacy Choice - 11/17/2009]
BioInvent signs licensing agreement with Daiich... [PipelineReview - 11/16/2009]
Drug Discovery Capabilities of ArQule Kinase In... [Business Wire via MSN Money - 11/16/2009]
Drug Discovery Capabilities of ArQule Kinase In... [Globe Investor - 11/16/2009]
xtremepicks.com: www.Xtremepicks.Com: Xtremepic... [RBC Dain Rauscher - 11/16/2009]
Seattle Genetics Initiates Phase I Clinical Tri... [Business Wire - 11/16/2009]
BioInvent, Daiichi Sankyo in antibody deal [Bio Spectrum Asia - 11/16/2009]
BioInvent inks licensing pact with Daiichi Sank... [PharmaBiz - 11/16/2009]
1 2 3 4 5 6 7 8 9
In Focus
  •  
Atul Sobti, Malvinder Singh, Svein Mathisen, [more]
  •  
Ranbaxy Laboratories LTD, BioInvent International AB, MorphoSys AG, [more]
  •  
Food and Drug Administration, American College of Cardiology, American Heart Association, [more]
  •  
Antibody, Biota, levofloxacin, [more]
  •  
Tokyo, New Delhi (India), Madras, [more]
  •  
Japan, India, Mexico, [more]
  •  
Medicine, Biotechnology, Medication, [more]
  •  
Pharma & Biotech, Health, Chemicals & Plastics, [more]
PharmaBiz, Individual.com, Economictimes, [more]
Content Volume
Network
Trends

Blogs

sort by: Date | Relevance
Got biotech contacts? [MaRS Blog - Innovation and Commercialization in ... - 11/10/2009]
Filed under: Emerging Science and Technology, Entrepreneurship and Business November 10th, 2009 by George @ MaRS It’s no secret that the biotech ...
News Roundup: Ranbaxy Eyes Acquisitions In India [VCCircle Feeds - 10/30/2009]
GM Close To Stake Sale Deal With SAIC - General Motors India could be readying to offload as much as 50% equity stake to Chinese truck maker SAIC Motor Corp. SAIC ...
Religare Plans Buyouts For Investment Banking T... [VCCircle Feeds - 10/08/2009]
Religare Capital Markets Ltd, a unit of financial services firm Religare Enterprises plans acquisitions or joint ventures to expand its investment banking and institutional ...
M&A Activity Bounces Back in July-Sept Quarter [VCCircle Feeds - 10/08/2009]
Slowdown in mergers & acquisition (M&A) activity appears to have bottomed out even though private equity (PE) transactions are yet to bounce back. The July-September ...
Strange Bedfellows: Rival Medical Firms Launch ... [WSJ.com: Health Blog - 10/02/2009]
A year ago, eight companies, including several fierce rivals, announced plans for an unusual $100 million study to address a huge question plaguing the market for ...
1 2 3 4 5

  •  
  •  
  •